KorAP: Find »[drukola/base=of & drukola/pos=noun]« with Poliqarp

<1 ...1683 1684 1685 ...1827 >

45,651 matches

Corola-website/Law/270343_a_271672

to changes in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication. Patient Education Counseling, 62: 104-110, 2006. 30. Karter AJ, Chan J, Parker MM et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care, 29(8).260, 2006. 31. DCCT New England Journal of Medicine, 329(14), September 30, 1993. 32. Nathen DM, Buse JB, Davison MB et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication. Patient Education Counseling, 62: 104-110, 2006. 30. Karter AJ, Chan J, Parker MM et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care, 29(8).260, 2006. 31. DCCT New England Journal of Medicine, 329(14), September 30, 1993. 32. Nathen DM, Buse JB, Davison MB et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care, 29(8).260, 2006. 31. DCCT New England Journal of Medicine, 329(14), September 30, 1993. 32. Nathen DM, Buse JB, Davison MB et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 8 1963-1972, 2006. 33. Aschner P

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
8 1963-1972, 2006. 33. Aschner P et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab, 12:252-261, 2010. 34. Național Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (CG34). London: NICE, 2006. 35. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
myocardial infarction. New England Journal of Medicine 339: 229-234, 1998. 36. Eddy DM, Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care 26: 3102-3110, 2002. 37. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine, 21: 238-245, 2004. 38. Stephens JW, Ambler G, Vallance P et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? European Journal of

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine, 21: 238-245, 2004. 38. Stephens JW, Ambler G, Vallance P et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? European Journal of Cardiovascular Prevention and Rehabilitation, 11: 521-528, 2004. 39. Guzder RN, Gatling W, Mullee MA et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine, 21: 238-245, 2004. 38. Stephens JW, Ambler G, Vallance P et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? European Journal of Cardiovascular Prevention and Rehabilitation, 11: 521-528, 2004. 39. Guzder RN, Gatling W, Mullee MA et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
et al. Framington, SCORE and DECODE do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care, 30: 1292-1293, 2007. 41. Stevens RJ, Kothari V, Adler AI et al. The UKPDS risk engine: a model for the risk of coronary heart diseasein type II diabetes (UKPDS 56). Clinical Science, 101: 671-679, 2001. 42. Tuomilehto J Rastenyte D. Epidemiology of macrovascular disease and hypertension in diabetes mellitus. Internațional textbook of diabetes mellitus, 2nd edn. Chichester: John Wiley, 1559-1583, 1997. 43

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
Rastenyte D. Epidemiology of macrovascular disease and hypertension in diabetes mellitus. Internațional textbook of diabetes mellitus, 2nd edn. Chichester: John Wiley, 1559-1583, 1997. 43. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. 366: 1267-1278, 2005. 44. Vijan S, Hayward RA, American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Annals

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
mellitus. Internațional textbook of diabetes mellitus, 2nd edn. Chichester: John Wiley, 1559-1583, 1997. 43. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. 366: 1267-1278, 2005. 44. Vijan S, Hayward RA, American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Annals of Internal Medicine, 140: 650-658, 2004. 45. Național Institute for

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
1997. 43. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. 366: 1267-1278, 2005. 44. Vijan S, Hayward RA, American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Annals of Internal Medicine, 140: 650-658, 2004. 45. Național Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events inpatients

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. 366: 1267-1278, 2005. 44. Vijan S, Hayward RA, American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Annals of Internal Medicine, 140: 650-658, 2004. 45. Național Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events inpatients at increased risk of developing cardiovascular disease or those with established cardiovascular disease (TA94). London: NICE

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Annals of Internal Medicine, 140: 650-658, 2004. 45. Național Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events inpatients at increased risk of developing cardiovascular disease or those with established cardiovascular disease (TA94). London: NICE, 2006. 46. Național Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygousfamilial and non-familial) hypercholesterolaemia (TA132). London: NICE, 2007. 47. Insull W, Kafonek S

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
TA94). London: NICE, 2006. 46. Național Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygousfamilial and non-familial) hypercholesterolaemia (TA132). London: NICE, 2007. 47. Insull W, Kafonek S, Goldner D et al. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. American Journal of Cardiolog, 87: 554-559, 2001. 48. Van Venrooij FV, van de Ree MA, Bots ML et al. Aggressive lipid lowering does not improve endothelial function in type 2

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
for the treatment of primary (heterozygousfamilial and non-familial) hypercholesterolaemia (TA132). London: NICE, 2007. 47. Insull W, Kafonek S, Goldner D et al. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. American Journal of Cardiolog, 87: 554-559, 2001. 48. Van Venrooij FV, van de Ree MA, Bots ML et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
DA, URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular Diabetology, 4:7, 2005. 51. Colhoun HM, Betteridge DJ, Durrington PN et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 48: 2482-2485, 2005. 52. Sever PS, Poulter NR, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular Diabetology, 4:7, 2005. 51. Colhoun HM, Betteridge DJ, Durrington PN et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 48: 2482-2485, 2005. 52. Sever PS, Poulter NR, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care, 29: 1220-1226, 2006. 54. Steiner G, Hamsten A, Hosking J et al. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet, 57: 905-910, 2001. 55. Vakkilainen J, Steiner G, Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 364: 331-337, 2004. 58. Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology, 90: 625-628, 2002. 59. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabetic Medicine, 24(4):377-383, 2007. 65. Raskin J, Smith TR, Wong K et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. Journal of Palliative Medicine, 9: 29-40, 2006. 66. Raskin J, Pritchett YL, Wang F et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine, 6

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
FJ, PerezMonteverde A, Nascimento O et al. Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response. British Journal of Diabetes Vascular Disease, 4: 173-178, 2004. 70. Richter RW, Portenoy R, Sharma U et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. Journal of Pain, 6: 253-260, 2005. 71. Rosenstock J, Tuchman M, Lamoreaux L et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain, 110

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
double-blind, placebo-controlled trial. Pain, 110: 628-638, 2004. 72. Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Current Opinion in Nephrology Hypertension, 12: 317-322, 2003. 73. Banerjee S, Ghosh US, Saha SJ. Role of GFR estimation in assessment of the status of nephropathy in type 2 diabetes mellitus. Journal of the Association of Physicians of India, 53:181-4, 2005. 74. Baskar V, Venugopal H, Holland MR et al. Clinical utility of estimated glomerular filtration

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Current Opinion in Nephrology Hypertension, 12: 317-322, 2003. 73. Banerjee S, Ghosh US, Saha SJ. Role of GFR estimation in assessment of the status of nephropathy in type 2 diabetes mellitus. Journal of the Association of Physicians of India, 53:181-4, 2005. 74. Baskar V, Venugopal H, Holland MR et al. Clinical utility of estimated glomerular filtration rates in predicting renal risk in a district

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
Hernandez JL et al. Utility of the Dipstick Micraltest II in the screening of microalbuminuria of diabetes mellitus type 2 and essential hypertension. Revista de Investigacion Clinica, 58: 190-19/, 2006. 76. Incerți J, Zelmanovitz T, Camargo JL et al. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrology Dialysis Transplantation, 20: 2402-2407, 2005. 77. Maclsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care, 27:1 95-200, 2004. 78. Middleton RJ, Foley

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]
Nephrology Dialysis Transplantation, 20: 2402-2407, 2005. 77. Maclsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care, 27:1 95-200, 2004. 78. Middleton RJ, Foley RN, Hegarty J et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrology Dialysis Transplantation, 21: 88-92, 2006. 79. Parikh CR, Fischer MJ, Estacio R et al. Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity [erratum appears in

GHID din 1 martie 2016 la Ordinul nr. 226/2015 , privind modificarea anexei nr. 12 la Ordinul nr. 1.059/2009. In: EUR-Lex (2016) [Corola-website/Law/270343_a_271672]